Anti-tumour necrosis factor (anti-TNF) therapy of patients with rheumatoid arthritis dates back to 1992, when the first proof-of-principle trials were performed in London by Maini and Feldmann. Considerable studies of the mechanism of action were performed, and insights into the way in which anti-TNF therapy delivers its benefit were obtained. In this brief review, certain aspects of knowledge acquired and the many gaps will be reviewed. Focus will be on the TNF-dependent cytokine cascade and...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
What have we learnt from targeted anti-TNF therapy?
If you are the owner of this record, you can report an update to it here: Report update to this record